医学
酒渣鼻
异维甲酸
痤疮
女孩
皮肤病科
奥马佐单抗
生活质量(医疗保健)
儿科
免疫球蛋白E
免疫学
心理学
发展心理学
抗体
护理部
作者
Zofia Mazurek-Durlak,Katarzyna Mularczyk,Przemko Kwinta,Grzegorz Lis,Ewa Cichocka‐Jarosz
出处
期刊:Allergologia et immunopathologia
[Codon Publications]
日期:2023-03-01
卷期号:52 (2): 23-31
被引量:1
标识
DOI:10.15586/aei.v52i2.978
摘要
Morbihan syndrome (MS) is characterized by solid facial edema, usually related to rosacea or acne vulgaris. The facial edema deforms the patient's features, can impair peripheral vision, and affects quality of life. Its pathophysiology remains unclear. The disease usually has a slow and chronic course. MS most commonly affects middle-aged Caucasian men with rosacea and is rare in people below 20 years of age. MS is a diagnosis of exclusion. There is no standard treatment for MS, though systemic isotretinoin and antihistamines are mainly used. We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.
科研通智能强力驱动
Strongly Powered by AbleSci AI